Green light for Sanofi's Teizeild in type 1 diabetes

Sanofi has received CHMP approval for the European marketing of Teizeild, intended for patients with stage 2 type 1 diabetes. This recommendation is based on the results of the TN-10 study, which demonstrated the drug's ability to delay progression to stage 3.

Teizeild, a monoclonal antibody, could become the first disease-modifying treatment for type 1 diabetes in Europe. Tested on patients aged eight and older, it has shown efficacy in keeping a greater proportion of them at stage 2. The drug's safety profile is consistent with previous studies.

Already approved in several countries, Sanofi is considering the next steps for the European market. Teizeild represents a breakthrough in the early management of diabetes, potentially revolutionizing a treatment paradigm that is decades old.